Added to YB: 2026-05-22
Pitch date: 2026-05-20
LQDA [neutral]
Liquidia Corporation
+1.46%
current return
Author Info
Value with a Catalyst covers long value oriented small and mid- cap investment ideas with a catalyst. Sign up for the newsletter.
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Market Cap
$5.5B
Pitch Price
$61.08
Price Target
N/A
Dividend
N/A
EV/EBITDA
113.85
P/E
253.03
EV/Sales
18.94
Sector
Pharmaceuticals
Category
growth
Liquidia - May 19 2026, Conference Transcript
LQDA (update): $520M run-rate sales (Q1 annualized), profitable w/ $30M cash flow, $70M adj EBITDA. PAH TAM $3B+, PH-ILD $3-5B (underpenetrated). Higher dosing vs competitors (185.5μg vs typical 9-12 breaths) drives better outcomes. Expanding sales force 33% in Q2. L606 next-gen 2x daily nebulizer, 2029 data readout. 8 clinical studies planned/active (transitions, PH-COPD pivotal 2027, PPF, Raynaud's). Litigation ruling pending (9 months late). Self-funding R&D from operations.
Read full article (14 min)